Skip to content

Memory and Attention Adaptation Training-Geriatrics (MAAT-G)

Mitigating Cancer-Related Cognitive Impairment in Older Adults With Breast Cancer Receiving Chemotherapy: Memory and Attention Adaptation Training-Geriatrics (MAAT-G) Phase I

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04230941
Enrollment
4
Registered
2020-01-18
Start date
2020-06-12
Completion date
2022-02-01
Last updated
2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer-related Problem/Condition, Cognitive Impairment

Brief summary

Cancer-related cognitive dysfunction (CRCD) affects up to 75% of patients receiving chemotherapy and older adults are at greater risk of developing CRCD, which can negatively affect their functional independence and quality of life. Memory and Attention Adaptation Training (MAAT) is a promising treatment for CRCD that improves perceived cognition in younger cancer survivors, but needs to be adapted for older adults to address their unique needs. The proposed study will adapt MAAT for older adults using feedback from key stakeholders (older adults with cancer and their caregivers), and test usability of the intervention.

Detailed description

Cancer-related cognitive dysfunction (CRCD) is a significant problem, affecting up to 75% of patients receiving chemotherapy. Older adults are at greater risk of developing CRCD which can negatively affect their functional independence and quality of life. Memory and Attention Adaptation Training (MAAT) is a promising tool that improves perceived cognition in younger cancer survivors with CRCD. For older adults with cancer, MAAT could be delivered alongside chemotherapy to mitigate the development of CRCD (when risk is highest) and CRCD-related effects on functional independence for older adults. However, MAAT will require adaptation to meet the unique needs of older adults to optimize usability and efficacy for this population. The overarching goal of this project is to adapt MAAT for older adults using input from patient and caregiver stakeholders (phase I), and subsequently gather data on the preliminary effects of the adapted MAAT (MAAT-Geriatrics \[G\]) on perceived cognition, objective cognitive measures and functional independence. The provided details pertain to Phase I of the study, which will focus on the adaptation process and usability testing.

Interventions

BEHAVIORALMAAT-G

Memory and Attention Adaptation Training (MAAT) is a cognitive-behavioral therapy (CBT)-based intervention for CRCD. As a CBT-based intervention, MAAT focuses on an individual's psychological response to injury as compared to the biological events triggering CRCD. MAAT is a series of manualized workshops delivered by a psychologist via video-conferencing, supplemented by a participant workbook, which provide instruction and practice with adaptive behavioral coping skills, stress management techniques, and compensation strategies. MAAT-G has been adapted to optimize usability. We are now testing the feasibility of MAAT-G in older cancer survivors with Mild Cognitive Impairment.

Sponsors

National Institute on Aging (NIA)
CollaboratorNIH
University of Rochester
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Intervention model description

Usability

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Patient Inclusion Criteria: 1. Have a diagnosis of invasive breast cancer 2. Planned to receive systemic therapy for breast cancer or actively receiving systemic therapy for breast cancer with two additional cycles remaining. 3. Be age 65 or older 4. Able to provide informed consent 5. Able to read and understand English (or possess a designated health care proxy that can do the same that was designated prior to the patient losing decision-making capabilities) Patient

Exclusion criteria

1. Have surgery planned within 3 months of consent 2. Patients who do not have decision-making capacity (decisionally or cognitively impaired) AND do NOT have a previously designated health care proxy (established prior to their cognitive impairment) available to sign consent 3. Patients with breast cancer receiving endocrine therapy as their only systemic therapy will not be eligible. Eligible Caregiver Inclusion Criteria: 1\. Selected by the patient when asked if there is a family member, partner, friend or caregiver \[age 21 or older\] with whom you discuss or who can be helpful in health-related matters; patients who cannot identify such a person (caregiver) will remain eligible for the study. Eligible Caregiver

Design outcomes

Primary

MeasureTime frameDescription
System Usability Scale (SUS)Post-Intervention (up to 2 weeks)The System Usability Scale is a metric to evaluate the usability of the intervention (Patients) and is scored 0 (minimum) to 100 (maximum). Higher scores indicate greater usability. A mean score \>68 is consisted with optimal usability.
Experience InterviewPost-Intervention (up to 2 weeks)Semi-structured interview with patients and caregivers about experience with MAAT-G. (Patients and caregivers) Qualitative Analysis of transcripts from participant/caregiver interviews will be analyzed for themes on intervention benefit and barriers and facilitators.

Countries

United States

Participant flow

Participants by arm

ArmCount
MAAT-G Intervention
MAAT-G Workshops & participant workbook use (10 workshops) MAAT-G: Memory and Attention Adaptation Training-Geriatrics (MAAT-G) is a cognitive-behavioral therapy (CBT)-based intervention for CRCD. As a CBT-based intervention, MAAT-G focuses on an individual's psychological response to injury as compared to the biological events triggering CRCD. MAAT-G is a series of manualized workshops delivered by a psychologist via video-conferencing, supplemented by a participant workbook, which provide instruction and practice with adaptive behavioral coping skills, stress management techniques, and compensation strategies. MAAT-G has been adapted to optimize usability. We are evaluating the usability of MAAT-G.
4
Caregiver
Caregivers were optional to enroll with patients. A caregiver was not required to enroll for a patient to participate.
1
Total5

Baseline characteristics

CharacteristicMAAT-G InterventionCaregiverTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
4 Participants1 Participants5 Participants
Age, Categorical
Between 18 and 65 years
0 Participants0 Participants0 Participants
Age, Continuous73.25 years78 years73.8 years
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants0 Participants0 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
3 Participants1 Participants4 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
1 Participants0 Participants1 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
0 Participants0 Participants0 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
4 Participants1 Participants5 Participants
Region of Enrollment
United States
4 Participants1 Participants5 Participants
Sex: Female, Male
Female
4 Participants0 Participants4 Participants
Sex: Female, Male
Male
0 Participants1 Participants1 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 40 / 1
other
Total, other adverse events
0 / 40 / 1
serious
Total, serious adverse events
0 / 40 / 1

Outcome results

Primary

Experience Interview

Semi-structured interview with patients and caregivers about experience with MAAT-G. (Patients and caregivers) Qualitative Analysis of transcripts from participant/caregiver interviews will be analyzed for themes on intervention benefit and barriers and facilitators.

Time frame: Post-Intervention (up to 2 weeks)

Population: MAX QDA Software utilized for qualitative analysis coding

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
MAAT-G InterventionExperience InterviewNumber of participants describing the MAAT-G intervention as beneficial4 Participants
MAAT-G InterventionExperience InterviewNumber of participants using study-based facilitators to overcome Telehealth barriers3 Participants
CaregiverExperience InterviewNumber of participants describing the MAAT-G intervention as beneficial1 Participants
CaregiverExperience InterviewNumber of participants using study-based facilitators to overcome Telehealth barriers1 Participants
Primary

System Usability Scale (SUS)

The System Usability Scale is a metric to evaluate the usability of the intervention (Patients) and is scored 0 (minimum) to 100 (maximum). Higher scores indicate greater usability. A mean score \>68 is consisted with optimal usability.

Time frame: Post-Intervention (up to 2 weeks)

ArmMeasureValue (MEAN)
MAAT-G InterventionSystem Usability Scale (SUS)90.6 score on a scale

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026